Article

Gregory J. Riely on the Identification and Treatment of MET Exon 14 Skipping Mutations

Author(s):

Gregory J. Riely

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Gregory J. Riely, associate attending physician, Memorial Sloan Kettering Cancer Center, discusses identifying and treating patients with MET exon 14 skipping mutations in lung cancer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Image of woman with brown hair.
Image of man with black hair.
Image of bald man.
Image of man.
Image of Kumar.
Related Content
picture of lungs
April 25th 2025

ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC

Ryan Scott
Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Among patients with advanced squamous NSCLC, ivonescimab plus chemo was associated with positive progression-free survival results: © Steph_photagraphies - stock.adobe.com.
April 23rd 2025

Ivonescimab Plus Chemo May Slow Advanced NSCLC Progression

Alex Biese
In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free survival results.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
LCI, in cooperation with a statewide consortium of leaders and healthcare organizations, today announced the launch of Screening Saves.
April 22nd 2025

LCI Launches Screening Saves Program

Lung Cancer Initiative (LCI)
Image of Lungs.
April 18th 2025

First Patient Dosed in a Phase 1/2 Trial for Small Cell Lung Cancer

Ryan Scott
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus immune checkpoint inhibitors.